Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically accompanies a big-money acquisition in the biopharma industry. | Merck ...

Daniele Ghilardi has reportedly accepted the proposal from Roma, so they hope to get a deal done with Hellas Verona for €10m.

Google has uploaded a new logo for Google Search Console. The logo looks like a variation of an analytics logo with a magnifying glass, with blue, green, yellow and a smidge of red in the logo.

Knife-wielding 'terrorist' mob storms wind farm project Agsm Aim's 30MW array under construction in Italy sustained substantial damage to equipment and vehicles Agsm Aim said the wind project received ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck & Co. has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive pulmonary disease treatment Ohtuvayre as it braces for the 2028 loss of ...

Merck is paying about $10 billion for Verona Pharma, expanding its respiratory disease drug portfolio.

Merck & Co. agreed to buy respiratory drugmaker Verona Pharma Plc for around $10 billion as part of its ongoing search for ways to fill the Keytruda-sized hole that will emerge over the next ...

Merck (MRK) plans a $10B acquisition of Verona Pharma (VRNA), boosting its lung disease portfolio.

Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss.

Merck & Co. is closing in on an approximately $10 billion deal to acquire respiratory drugmaker Verona Pharma, the Financial Times reported.

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal.